Return on Equity (ROE)
Updated 8h ago
Sector Performance
7th percentileCAG
-25.1%
Sector Median
13.8%
Sector Avg
31.4%
Deep Analysis
CAG’s current Return on Equity (ROE) of -25.1% means the company generated a net loss relative to the shareholders’ equity invested in the business — a negative ROE indicates the company is destroying equity value, not creating it.
For context, the sector median ROE is 13.8%, and CAG ranks in the 7th percentile among its sector peers, meaning 93% of peers have a higher ROE. The year-over-year change is not available, but the quarter-over-quarter change is -4,920.0% — a sharp deterioration from -0.5% in the prior period. Combining a deeply negative ROE level with a massive quarter-over-quarter decline signals elevated investment risk, as the company’s profitability has turned severely negative in a short timeframe. This metric directly supports the overall CAUTIOUS verdict on CAG, since poor and rapidly worsening returns on equity are consistent with a cautious stance.
Frequently Asked Questions
What does the Return on Equity (ROE) tell investors about CAG?
ROE measures how effectively management turns equity into profit. Consistently above 15% is typically considered strong. Negative equity distorts this metric.
How is the Return on Equity (ROE) calculated?
Return on Equity (ROE) is calculated as: Net Income / Shareholders' Equity.
Who are CAG's closest peers by Return on Equity (ROE)?
The closest peers by Return on Equity (ROE) include: MRNA (-36.6%), FICO (-37.3%), XRAY (-37.7%), VRSN (-38.3%), MSCI (-45.3%).
The Formula
Net Income / Shareholders' Equity
Why It Matters
ROE measures how effectively management turns equity into profit. Consistently above 15% is typically considered strong. Negative equity distorts this metric.
Master CAG's Valuation
Get the complete institutional research report covering all fundamental and technical metrics.
View full CAG research report →CAG
-25.1%
Sector Median
13.8%
Sector Avg
31.4%
How CAG's Return on Equity (ROE) compares to sector peers.
Also Analyze
Not financial advice. Research tool only. Data may be delayed.